References
- Bissonnette R. Etanercept for the treatment of psoriasis. Skin Therapy Lett. 2006;11:1–4.
- Tan JK, Aphale A, Malaviya R, Sun Y, Gottlieb AB. Mechanisms of action of etanercept in psoriasis. J Investig Dermatol Symp Proc. 2007;12:38–45.
- Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304–1312.
- Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007;143:719–726.
- Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014–2022.
- Kircik L, Bagel J, Korman N, Menter A, Elmets CA, Koo J, Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes. J Drugs Dermatol. 2008;7:245–253.
- Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010;62:114–135.
- Mahajan R, Kaur I, Kanwar AJ Methotrexate/narrowband UVB phototherapy combination vs. narrowband UVB phototherapy in the treatment of chronic plaque-type psoriasis–a randomized single-blinded placebo-controlled study. J Eur Acad Dermatol Venereol. 2010;24:595–600.
- Wolf P, Hofer A, Legat FJ, Bretterklieber A, Weger W, Salmhofer W, Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept. Br J Dermatol. 2009;160:186–189.
- Legat FJ, Hofer A, Wackernagel A, Salmhofer W, Quehenberger F, Kerl H, Narrowband UV-B phototherapy, alefacept, and clearance of psoriasis. Arch Dermatol. 2007;143:1016–1022.
- Foley P, Quirk C, Sullivan J, Dolianitis C, Hack S, Thirunavukkarasu K, Combining etanercept with traditional agents in the treatment of psoriasis: a review of the clinical evidence. J Eur Acad Dermatol Venereol. 2010;24:1135–1143.
- Fredriksson T, Pettersson U. Severe psoriasis–oral therapy with a new retinoid. Dermatologica. 1978;157:238–244.
- Hon-Sum Ko MDMO, Division of Dermatologic and Dental Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda MD. Clinical Design for Psoriasis. Dermatologic and Ophthalmic Drugs Advisory Committee 49th Meeting Open Session (Volume II); 1998 Mar 20; Gaithersburg MD.
- Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–216.
- Evers AW, Kleinpenning MM, Smits T, Boezeman J, van de Kerkhof PC, Kraaimaat FW, Treatment nonadherence and long-term effects of narrowband UV-B therapy in patients with psoriasis. Arch Dermatol. 2010;146:198–199.
- Richards HL, Fortune DG, Griffiths CE. Adherence to treatment in patients with psoriasis. J Eur Acad Dermatol Venereol. 2006;20:370–379.
- Ali SM, Brodell RT, Balkrishnan R, Feldman SR. Poor adherence to treatments: a fundamental principle of dermatology. Arch Dermatol. 2007;143:912–915.
- Sabate E Adherence to long-term therapies: evidence for action. [WWW document]: world health organization. Geneva, Switzerland; 2003 [11 November 2010]; Available from: http://apps.who.int/medicinedocs/en/d/Js4883e/1.html